Gregory Ferenstein
Gregory Ferenstein is a senior fellow in drug policy at Reason Foundation.
-
Psilocybin access would improve mental health care in Massachusetts
Ballot Question 4 would create a regulated framework for legal, professionally facilitated psychedelic services and therapy.
-
Psychedelics Policy Newsletter: MDMA rejection, advocating for lower state fees in Colorado, and more
Plus: A profile of ibogaine advocate Bryan Hubbard, the Drug Enforcement Administration head worries about ketamine, and more.
-
State psychedelics legalization and policy roundup — September 2024
A Massachusetts ballot initiative moves forward, Colorado considers high business application and renewal fees, and more.
-
Colorado should rethink proposed psychedelic application fees
There are several areas where the draft permanent rules on fees for psychedelic applications proposed by the Colorado Department of Revenue could be enhanced.
-
Psychedelics Policy Newsletter: A glimpse into Colorado after psychedelics legalization, a gathering of conservative legislators, and more
Plus: Food and Drug Administration approval of MDMA is tentative, the psychedelic origins of Whole Foods, and more.
-
State psychedelics legalization and policy roundup — July 2024
Psychedelics on the ballot in Massachusetts, Colorado proposes new regulatory rules, and Arizona Gov. Hobbs vetoes a psychedelics bill.
-
Colorado could improve regulatory rules regarding psychedelic use
As Colorado establishes an operating regulatory framework for The Natural Medicine Health Act, there is room for improvement in rulemaking.
-
A glimpse into Colorado’s emerging legal pyschedelics scene
Colorado became the first state in America where residents can legally grow and share psilocybin mushrooms in 2022.
-
How the FDA can safely approve a promising but controversial mental health drug
The FDA’s existing processes may be able to address the advisory committee’s worries about the previous tests.
-
States can legalize MDMA for pharmaceutical use even if the federal government does not
States have many options when considering the legalization or decriminalization of psychedelic medicines within their borders.
-
New Jersey Senate Bill 2283 would decriminalize psilocybin
Senate Bill 2283 would allow personal possession and cultivation of psilocybin in a private residence.
-
Psychedelics Policy Newsletter: Massachusetts ballot initiative would foster access, state legislature momentum stalls, and more
Plus: The National Institute of Health awards money for addiction research, a Michigan poll signals interest in psychedelics, and more.
-
State psychedelics legalization and policy roundup — May 2024
Legislative progress slows, a Massachusetts ballot initiative moves forward, and Colorado rejects censorship.
-
Assessing Michigan voters’ support for legalizing psychedelic therapy
An online survey finds 65% of registered voters in Michigan say they support allowing licensed health professionals to legally prescribe psychedelics.
-
California should legalize psychedelics and learn from its marijuana regulation mistakes
The state’s high cannabis taxes and burdensome regulations make legal marijuana products expensive and keep the illicit market thriving.
-
Massachusetts should allow psychedelic therapy
A Massachusetts ballot initiative would create a regulated framework for legal, professionally facilitated psychedelic services and therapy.
-
Colorado’s rejection of Senate Bill 24-158 is good for privacy, free speech
For now, the defeat of Colorado Senate Bill 24-158 was a win for consumers, privacy and free speech.
-
Psychedelics Policy Newsletter: A retail system model, ibogaine research, and legalization updates
A model that would reduce costs and increase consumer access to psychedelics by streamlining the overall regulatory burden.
